4:01 PM ET
10-Q
Financial Results
Actuate Therapeutics Q3 2026 Results: Net Loss of $3.42M, Loss Narrows
Actuate Therapeutics reported a net loss of $13.9 million for the nine months ended September 30, 2026, compared to $17.7 million in the prior year period. The company's cash position decreased significantly to $2.1 million, resulting in a working capital deficit and a stated going concern uncertainty as it continues to fund clinical development of elraglusib.
- Key figure
- Net loss $3.42M